The DOI matches its Crossref record; 356 of the 356 references it cites were found in a registry or an index.
Catechol-O-methyltransferase (COMT): Biochemistry, Molecular Biology, Pharmacology, and Clinical Efficacy of the New Selective COMT Inhibitors
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The common rs4680 Val 158 Met single nucleotide polymorphism (SNP) leads to a reduction of COMT enzymatic activity in Met carriers (6-8).”
From Influence of the COMT genotype on working memory and brain activity changes during development (2011) · cites this paper as [7]
Citations
Cites
Lachman, H. M., Papolos, D. F., Saito, T., Yu, Y.-M., Szumlanski, C. L., & Weinshilboum, R. M. (1996) · Pharmacogenetics · doi:10.1097/00008571-199606000-00007 · Cited by 1,788
Enzymatic O-methylation of epinephrine and other catechols
Axelrod, J., & Tomchick, R. (1958) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64731-3 · Cited by 1,283
Lotta, T. I., Vidgren, J., Tilgmann, C., Ulmanen, I., Melén, K., Julkunen, I., & Taskinen, J. (1995) · Biochemistry · doi:10.1021/bi00013a008 · Cited by 1,167
Functional role of estrogen metabolism in target cells: review and perspectives
Zhu, B. T. (1998) · Carcinogenesis · doi:10.1093/carcin/19.1.1 · Cited by 970
Age at first birth and breast cancer risk.
MacMahon, B., Cole, P. T., Lin, T. M., Lowe, C. R., Mirra, A. P., Ravnihar, B., Salber, E. J., Valaoras, V. G., & Yuasa, S. (1970) · Europe PMC (PubMed Central) · Cited by 878
Gogos, J. A., Morgan, M., Luine, V., Santha, M., Ogawa, S., Pfaff, D., & Karayiorgou, M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.17.9991 · Cited by 864
Fotsis, T., Zhang, Y., Pepper, M. S., Adlercreutz, H., Montesano, R., Nawroth, P. P., & Schweigerer, L. (1994) · Nature · doi:10.1038/368237a0 · Cited by 730
Molecular origin of cancer: Catechol estrogen-3,4-quinones as endogenous tumor initiators
Cavalieri, E. L., Stack, D. E., Devanesan, P. D., Todorović, R., Dwivedy, I., Higginbotham, S. M., Johansson, S. L., Patil, K. D., Gross, M. L., Gooden, J. K., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.20.10937 · Cited by 728
17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1.
Hayes, C. L., Spink, D. C., Spink, B. C., Cao, J. Q., Walker, N. J., & Sutter, T. R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.18.9776 · Cited by 631
Catecholamine metabolism: basic aspects and clinical significance.
Kopin, I. J. (1985) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06859-0 · Cited by 582
Research works printed but not linked: 13
- Davis, 1997, Effects of tolcapone withdrawal after 6 week treatment in Parkinsonian patients who exhibit end-of-dose wearing off (Abstract), Mov Disord, 12, 97
- European Medicine Evaluation Agency Press release: Recommendation for the suspension of the marketing authorization for Tasmar (tolcapone), London, 1998.
- Gordin, 1998, Pharmacokinetics of entacapone and catechol-O-methyltransferase (COMT) inhibition after frequent multiple dosing of entacapone and effect on levodopa metabolism, Eur J Neurol, 5, S165
- Gordin, 1998, Pharmacokinetics of the COMT inhibitor entacapone in liver failure and the effect of entacapone on liver function (Abstract), Neurology, 50, 387
- Grossman, 1992, Identification of the possible basis for inherited differences in human catechol-O-methyltransferase (Abstract), Trans Neurosci Soc, 18, 70
- Heikkinen H, Pentikäinen PJ, Saraheimo M, Ahtila S, Ottoila P Pharmacokinetics of entacapone, a new COMT-inhibitor, in man: A study using stable isotope technique (Abstract). 11th International Symposium on Parkinson’s Disease; March 26–30, Rome. 301 p, 1994.
- Jorga, 1997, Why should tolcapone be given at a lower dose to patients with liver cirrhosis?, Clin Pharmacol Ther, 61, 183
- Myllylä, 1997, Effect of entacapone as an adjunct to Sinemet and Madopar on the pharmacokinetics of levodopa in parkinsonian patients (Abstract), Mov Disord, 12, 103
- Oechsner, 1998, Elevated serum levels of dihydroxyphenylacetic acid (DOPAC) and dopamine after catechol-O-methyltransferase (COMT) inhibition (Abstract), Eur J Neurol, 5, 169
- Pentikäinen, 1990, Fate of nitecapone, a new catechol-O-methyltransferase inhibitor in man: A study with double isotope technique (Abstract), Clin Pharmacol Ther, 47, 156
- Pentikäinen, 1989, Human pharmacokinetics of OR-462, a new catechol-O-methyltransferase inhibitor (Abstract), Eur J Clin Pharmacol, 36, 110
- Riley, 1996, No evidence for linkage of chromosome 22 markers to schizophrenia in Southern African Bantu-speaking families, Am J Med Gen (Neuropsychiat Gen), 67, 515, 10.1002/(SICI)1096-8628(19961122)67:6<515::AID-AJMG2>3.0.CO;2-G · DOI
- Welsh, 1995, Improving quality of life in Parkinson’s disease: An experimental study of tolcapone (Abstract), Qual Life Res, 4, 503
Cited by
Sorted by citations
Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
Harrison, P. J., & Weinberger, D. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001558 · Cited by 2,020
Caspi, A., Moffitt, T. E., Cannon, M., McClay, J., Murray, R., Harrington, H., Taylor, A., Arseneault, L., Williams, B., Braithwaite, A., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.01.026 · Cited by 1,409
Understanding the contribution of synonymous mutations to human disease
Sauna, Z. E., & Kimchi-Sarfaty, C. (2011) · Nature Reviews Genetics · doi:10.1038/nrg3051 · Cited by 1,022
Mattay, V. S., Goldberg, T. E., Fera, F., Hariri, A. R., Tessitore, A., Egan, M. F., Kolachana, B., Callicott, J. H., & Weinberger, D. R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0931309100 · Cited by 893
The Neurodevelopmental Hypothesis of Schizophrenia, Revisited
Fatemi, S. H., & Folsom, T. D. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn187 · Cited by 860
Nackley, A. G., Shabalina, S. A., Tchivileva, I. E., Satterfield, K., Korchynskyi, O., Makarov, S. S., Maixner, W., & Diatchenko, L. (2006) · Science · doi:10.1126/science.1131262 · Cited by 848
Catechol- O -Methyltransferase Genotype and Dopamine Regulation in the Human Brain
Akil, M., Kolachana, B. S., Rothmond, D. A., Hyde, T. M., Weinberger, D. R., & Kleinman, J. E. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-06-02008.2003 · Cited by 325
Tolcapone improves cognition and cortical information processing in normal human subjects
Apud, J. A., Mattay, V., Chen, J., Kolachana, B. S., Callicott, J. H., Rasetti, R., Alce, G., Iudicello, J. E., Akbar, N., Egan, M. F., et al. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301227 · Cited by 242
Reinforcement learning in depression: a review of computational research
Chen, C., Takahashi, T., Nakagawa, S., Inoue, T., & Kusumi, I. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.05.005 · Cited by 233
Krumsiek, J., Suhre, K., Evans, A. M., Mitchell, M. W., Mohney, R. P., Milburn, M. V., Wägele, B., Römisch-Margl, W., Illig, T., Adamski, J., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1003005 · Cited by 197
“COMT is responsible for the inactivation of catecholamines such as L-dopa and various neuroactive drugs by O-methylation [35].”
BackgroundMedina, M. Á., Urdiales, J. L., Rodríguez-Caso, C., Ramírez, F. J., & Sánchez-Jiménez, F. (2003) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/713609209 · Cited by 198
Tunbridge, E., Weickert, C., Kleinman, J., Herman, M., Chen, J., Kolachana, B., Harrison, P., & Weinberger, D. (2007) · Cerebral Cortex · doi:10.1093/cercor/bhl032 · Cited by 197
Influence of the COMT genotype on working memory and brain activity changes during development
Dumontheil, I., Roggeman, C., Ziermans, T., Peyrard-Janvid, M., Matsson, H., Kere, J., & Klingberg, T. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.02.027 · Cited by 165
Dempster, E. L., Mill, J., Craig, I. W., & Collier, D. A. (2006) · BMC Medical Genetics · doi:10.1186/1471-2350-7-10 · Cited by 129
From an Executive Network to Executive Control: A Computational Model of the n-back Task
Chatham, C. H., Herd, S. A., Brant, A. M., Hazy, T. E., Miyake, A., O'Reilly, R., & Friedman, N. P. (2011) · Journal of Cognitive Neuroscience · doi:10.1162/jocn_a_00047 · Cited by 115
Pharmacogenetics of antidepressants
Crisafulli, C., Fabbri, C., Porcelli, S., Drago, A., Spina, E., De Ronchi, D., & Serretti, A. (2011) · Frontiers in Pharmacology · doi:10.3389/fphar.2011.00006 · Cited by 113
Influence of SLC6A3 and COMT variation on neural activation during response inhibition
Congdon, E., Constable, R. T., Lesch, K. P., & Canli, T. (2009) · Biological Psychology · doi:10.1016/j.biopsycho.2009.03.005 · Cited by 103
Attention-Deficit/Hyperactivity Disorder Pharmacogenomics
McGough, J. J. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.10.021 · Cited by 92
Qin, S., Cousijn, H., Rijpkema, M., Luo, J., Franke, B., Hermans, E. J., & Fernández, G. (2012) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2012.00016 · Cited by 83
“Second, exposure to highly aversive films in combination with selfreferencing instruction meets the requirements for the physiological stress response in humans, particularly with activation of the sympatho-adrenomedullary system (SAM) and substantial elevation of epinephrine and norepinephrine levels, as described by…”
BackgroundPsychopathological aspects of dopaminergic gene polymorphisms in adolescence and young adulthood
Nemoda, Z., Szekely, A., & Sasvari-Szekely, M. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.04.002 · Cited by 78
Hevir, N., Šinkovec, J., & Rižner, T. L. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.09.011 · Cited by 69
Study of the Catechol‐O‐Methyltransferase (COMT) Gene with High Aggression in Children
Hirata, Y., Zai, C. C., Nowrouzi, B., Beitchman, J. H., & Kennedy, J. L. (2013) · Aggressive Behavior · doi:10.1002/ab.21448 · Cited by 65
Visschers, R. G. J., Luyer, M. D., Schaap, F. G., Olde Damink, S. W. M., & Soeters, P. B. (2013) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e32836410a4 · Cited by 60
Association Between Hypnotizability and the Catechol-O-Methyltransferase (COMT) Polymorphism
Szekely, A., Kovacs-Nagy, R., Bányai, É. I., Gősi-Greguss, A. C., Varga, K., Halmai, Z., Ronai, Z., & Sasvari-Szekely, M. (2010) · International Journal of Clinical and Experimental Hypnosis · doi:10.1080/00207141003760827 · Cited by 53
Cerasa, A., Cherubini, A., Quattrone, A., Gioia, M. C., Tarantino, P., Annesi, G., Assogna, F., Caltagirone, C., & Spalletta, G. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.02.040 · Cited by 34
Walder, D. J., Trotman, H. D., Cubells, J. F., Brasfield, J., Tang, Y.-L., & Walker, E. F. (2010) · Psychiatric Genetics · doi:10.1097/ypg.0b013e32833a1ff3 · Cited by 34
Gurvich, C., & Rossell, S. L. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.11.045 · Cited by 33
Lesion of the Cerebellar Noradrenergic Innervation Enhances the Harmaline-Induced Tremor in Rats
Kolasiewicz, W., Kuter, K., Nowak, P., Pastuszka, A., & Ossowska, K. (2011) · The Cerebellum · doi:10.1007/s12311-011-0250-9 · Cited by 14
Montel Hayes, R., Mason, C. E., & Miller, J. J. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1671122 · Cited by 5
Metadata
- Authors
- Männistö, P. T., & Kaakkola, S.
- Affiliations
- University of Eastern Finland (FI)
- ORCID
- Männistö, Pekka T.
- Venue
- Pharmacological Reviews
- Publisher
- Elsevier BV
- Published
- 1999-12
- Volume
- 51
- Issue
- 4
- Pages
- 593-628
- ISSN
- 0031-6997 (ISSN-L)
- OpenAlex
- W2131721815
- Cited by
- 1,068
- References
- 356
- Citations by year
- 2026: 18 · 2025: 19 · 2024: 14 · 2023: 19 · 2022: 19 · 2021: 35 · 2020: 42 · 2019: 41 · 2018: 38 · 2017: 56 · 2016: 52 · 2015: 48 · 2014: 58 · 2013: 68 · 2012: 58
- FWCI
- 15.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Pharmacological Reviews (publishedVersion)
- PubMed (publishedVersion)
- PubMed
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- catechol-O-methyltransferase, COMT inhibitors, enzyme kinetics, clinical efficacy
- MeSH terms
- Animals, Catechol O-Methyltransferase, Clinical Trials as Topic, Enzyme Inhibitors, Humans, Catechol O-Methyltransferase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
